Latest Research And Development News

Neometals Ltd reveals ongoing delays in receiving A$5 million from Omaha Value Holdings for its Tranche 2 placement, with subscription funds now expected in multiple instalments. The company maintains its cash preservation measures amid uncertainty over final settlement timing.

Objective Corporation loses a longstanding Department of Defence support contract, impacting future recurring revenue but maintaining a commitment to sovereign tech innovation.

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.

Venus Metals Corporation has secured $47 million from selling its Youanmi Gold Project royalty, while exploration at Henderson and Youanmi Base Metals projects reveals promising targets. The company also initiates titanium extraction R&D and plans special dividends for shareholders.

Papyrus Australia reached a key production milestone by delivering 200 biodegradable Collar Keeper® samples to TBS Mining Solutions, confirming its manufacturing scalability. The company’s May cash flow shows a steady funding runway amid ongoing R&D and commercialisation efforts.

ClearVue Technologies is inviting eligible shareholders to participate in a $1 million Share Purchase Plan at a discount, following a $5 million institutional placement. The capital raised will support ERP rollout, R&D, and working capital.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.

Right Resources has locked in a second tranche of A$755,000 in non-dilutive R&D funding for FY2026, boosting its collaboration with the University of Tasmania's CODES to deepen understanding of mineral systems in the Tumbarumba district.

Venus Metals has unveiled promising auger soil sampling results at its Henderson Gold Project and significant base metals anomalies at Youanmi, alongside initiating a titanium extraction research program with Murdoch University.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.